fbpx

Glycemic Control Reduces Progression of Diabetic Retinopathy

Intensive and careful control of blood sugar levels in diabetics can cut their risk of diabetic retinopathy in half, according to a new study from the NIH.

The results of the study, a follow-up to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study, were presented at the American Diabetes Association annual meeting in New Orleans on June 11, and the results were published in the journal Diabetes Care.

“This study sends a powerful message to people with type 2 diabetes who worry about losing vision,” said Emily Chew, M.D., deputy director of the NEI Division of Epidemiology and Clinical Applications and lead author of the study report. “Well-controlled glycemia, or blood sugar level, has a positive, measurable, and lasting effect on eye health.”

The study lasted three and a half years, and progression of diabetic retinopathy was determined to have occurred if the patient required laser surgery, a vitrectomy or if the patient advanced three levels in the Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.

Regular treatment of fenofibrate was supported by the study, reducing diabetic retinopathy by one third as long as the patient was taking fenofibrate regularly. Fenofibrate was approved as a treatment for diabetic retinopathy in Australia in 2013, but is not approved in Canada or the United States.

Full article: http://care.diabetesjournals.org/content/early/2016/06/10/dc16-0024

Related Reading: A New Culprit in Diabetic Retinopathy, A New Technique for Assessing Diabetic Retinopathy

Featured Posts

EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read more
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read more
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read more
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read more
EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read More
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read More
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read More
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read More
EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read more
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read more
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read more
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read more
EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read more
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read more
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read more
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read more